Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated. The approval is not reimbursed by Japan’s healthcare system, and patients will be responsible for the costs.
In the Japanese orthopaedic market, large joint reconstruction is the dominant segment. Learn more about the region from ORTHOWORLD’s intelligence report, The Japanese Orthopaedic Market.
Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated....
Cytori Therapeutics announced that Cytori Cell Therapy™ was approved for clinical use to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic under the Japanese Act on the Safety of Regenerative Medicine.
The approval is limited to facilities under the clinic’s umbrella and does not restrict the number of patients that can be treated. The approval is not reimbursed by Japan’s healthcare system, and patients will be responsible for the costs.
In the Japanese orthopaedic market, large joint reconstruction is the dominant segment. Learn more about the region from ORTHOWORLD’s intelligence report, The Japanese Orthopaedic Market.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
